[
    [
        {
            "time": "",
            "original_text": "益方生物IPO被暂缓表决，专利和商业秘密纠纷疑云待解",
            "features": {
                "keywords": [
                    "益方生物",
                    "IPO",
                    "暂缓表决",
                    "专利纠纷",
                    "商业秘密"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "益方生物IPO被暂缓表决，专利和商业秘密纠纷疑云待解",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "西南证券医药2022年度策略：未来医药估值有望均衡，“穿越医保”和“疫情脱敏”是两条核心主线",
            "features": {
                "keywords": [
                    "西南证券",
                    "医药",
                    "2022年度策略",
                    "估值均衡",
                    "穿越医保",
                    "疫情脱敏"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "西南证券医药2022年度策略：未来医药估值有望均衡，“穿越医保”和“疫情脱敏”是两条核心主线",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "贝达药业于浙江成立医药科技公司，注册资本5000万元",
            "features": {
                "keywords": [
                    "贝达药业",
                    "医药科技公司",
                    "浙江",
                    "注册资本",
                    "5000万元"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业于浙江成立医药科技公司，注册资本5000万元",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]